That is why it was not surprising that recently first the U.S. Senate , and within a week later the House of Representatives overwhelmingly passed the Prescription Drug UserFee Act (PDUFA), which generates the vast majority of the federal government’s
budget for the Food and Drug Administration’s (FDA) reviewing new medications.
This is one of the
legitimate and valuable functions of the FDA.
The other is to provide the oversight to ensure a safe food supply forAmericans.
But, Washington
being Washington, nothing is as simple as it seems.
Lobbyists,staffers with a particular political agenda, and special interests of Congressional Representatives and Senators have too often created a synergy that betrays the very purpose of agencies such asthe FDA by making it a surrogate for implementing policies that benefitthe particular and limited goals of those who would stand to profit, rather than doing what is best for Americans.
This occurs
because special interests are able to co-opt the intent of the legislativeprocess by having Congressmen and Senators insert onerous elements in thebills, elements skillfully crafted to seem to be in accordance with the purposeof the legislation.
No lobby is
better at this than the Pharmaceutical industry and its trade group PhRMA.
For many years,
we have published blogs detailing the network of the many front groups that PhRMA has created under the guise of ‘protecting’ the safety of prescription
medicines sold in the United States, but which are actually meant to make the
US a ‘safe haven’ for the highest prescription medicine prices in the world.
For more than 12
years, PhRMA and its members have used their vast army of lobbyists and their seemingly unlimited financial resources to deny the right of Americans to have
access to safe,affordable brand-name medicines from licensed, registered
pharmacies in Tier One countries, whose standards of safety and oversight meet or
exceed those of the US.
They have had
some successes, primary by inserting ‘poison pill’ amendments to legislationpassed by the Senate (many times) requiring the Secretary of Health and HumanServices (HHS) to ‘certify’ the safety of each and every prescription medicine personally imported, effectively killing the legislation.
But, a
distinguishing characteristic is that they never seem to give up. However, even with their vast expenditures,
Pharma is not invincible. But, it is persistent, as the following record of
creating mischief illustrates:
Over the years,
working in collusion with the supportive staff of the FDA, opponents of
personally imported medicines have attempted a number of tactics:
- · Random and ill-founded seizures of legitimate prescription medicines by Customs Inspectors, extending even to intimidation of the Elderly persons, who were denied their vital medicines by the seizures, by demanding that they sign letters prepared by Customs in which the Seniors purchasing the medicine ‘admitted’ to being ‘guilty’ of importing ‘illegal’ medicines.
o
When
Congress learned of the practices of Customs, it quickly passed legislationforbidding the seizures and ending the Customs involvement.
- · Attemptsto deter personal importation by attempting to lump prescription medicines fromoutside the US as ‘bogus’ and potentially dangerous to the health of Americans.
o
Fortunately,
the common sense of the American public has prevailed, and the record is clear
regarding the safety and efficacy of imported medicines from reputable
sources. This has been validated by
independent studies, as well as Americans demonstrating that they do indeed
have the ability to make responsible decisions and the ability to distinguish
between legitimate sources for safe, affordable medicines.
o
Ironically,
the case can be made that if Pharma were to expend the same amount of energy
towards reciprocity with Tier One countries, as it and the FDA have now done regarding
inspections of ingredients for the manufacture of pharmaceuticals, such action could be beneficial in attacking
the challenge of bogus pharmacies.
o
In
what was a blatant betrayal of Candidate Obama’s pledge of support for personal
importation, the Obama Administration engaged in ‘secret’ deal-making with Pharma in which the Administration
pledged to drop support for personal importation in return for PhRMA’s pledge
not to engage a ‘Harry and Louise’ type campaign (which deterred President Bill
Clinton’s Administration in its attempts at healthcare reform) against what the
President hoped to be his ‘legacy’ legislative accomplishment. Recently
released emails between PhRMA and the White House should be ‘must reading’for anyone with indignation over the influence of powerful lobbying groups. Ironically, the lack of transparency might be responsible for the many flaws in Obamacare--flaws that could have been avoided if there had been more opportunity for citizen input with open sessions, and which might be responsible for the legislation's constitutionality being decided by the US Supreme Court. The outcome could affect a number of situations, including, if it is overturned, the possibility of PhRMA declaring that all deals are void.
o
http://rxforamericanhealth.blogspot.com/2011/11/stop-online-piracy-act-endangers-health.html in which it attempted to use language that would
have given legislative sanction to Pharma’s battle against personal
importation. The law of unintendedconsequences was exemplified by a ‘blackout’ and disruption of the Internet,
the coming together of seniors’ groups with technical interest groups, resulting
in more than 100,000 letters and emails sent by America’s elderly to Congress and the Senate.
However, the
thrill of victory was short-lived as Pharma turned its attention to PDUFA,
which because of its ‘must-pass’ quality, has problematic language in both the
Senate and House bill.
The Senate bill contains a provision from Senator Tom Harkin (D-IA) that might be open to interpretation of the FDA that pharmacies in other countries involved in personal importation must register with the FDA.
In conversations with the Senator's office and designees, we have been assured that the Senator continues to 'support' personal importation, and had worked with the FDA to assure that no action is taken against personal importation, but significantly when the contact with the Majority Office, the staff member said that the Conference Committee will not add language similar to that of previous bills to specifically exempt personally imported prescription medicines, because there is 'no intent' that pharmacies are included in the registration requirement. We were told that the language is intended for ingredients manufacturers in other countries.
We have, however, been told that the presumed members of the Conference Committee are reportedly meeting informally and in secret, causing us to wonder if they will ever learn,even after hobbling together the Rube Goldberg healthcare proposal now being considered by the Supreme Court.
But, it in the House of Representatives when the most onerous language can be found. Section 805 would authorize the Secretaries of HHS and Homeland Security to seize and immediately destroy and medicine that they deem to be potentially harmful to Americans' health OR (my emphasis) with a value of less than $2000.
That is why it is gratifying to see the courage of Rep. Joanne Emerson (R-MO 8)in making the record on what advocates believe is the latest subterfuge of PhRMA to attempt to co-opt legislation for its own purposes and to open a new front on its continuing battle against personal importation--this time with the sanction of the legislative process.
Rep. Emerson's statement follows:
"MR. SPEAKER, I want to express my support for the
reauthorization of the Food and Drug Administration (FDA) under consideration
today. The FDA provides essential
safeguards for patients in America and around the world, while making possible
new treatments and therapies for diseases and conditions which affect
millions. This bill supports greater
speed of generic medications to market and assures much needed drugs to treat
cancer will get to the patients who need them.
"However, one provision (Section 805) in this legislation
causes me special concern. The section
includes the new authority for the Secretary of Health and Human Services to
consult with the Department of Homeland Security to cause the destruction of any
drug "that has reasonable probability of causing serious adverse health
consequences or death. or that is valued at an amount that is $2,000 or
less." This section poses a serious
concern to hundreds of thousands of Americans who receive their drugs by mail
from licensed and regulated pharmacies in Canada and other foreign countries.
"For these patients, these American consumers, there is
often only one choice beyond a Canadian pharmacy, and that is to not purchase
the medicines they need at all.
Patients expecting receipt of legitimate prescriptions,
written by their doctor and filled by a licensed pharmacy in Canada, could have
their shipment of medication destroyed without receiving any notification
either before or after the federal government takes that action. A bus full of senior citizens which crosses
the border into Canada to visit a pharmacy where they can fill their
prescriptions for one-third the price of the same medications in Canada could
have their pill bottles seized at the border, their meager budget for their
monthly health care expenses already exhausted.
This is not good policy, nor is it what Americans expect from a free
market.
"This language threatens a critical, cost-effective supply
of medications and pharmaceuticals.
These drugs are exactly the same as their counterparts sold in
America. I urge further discussion of
this critical issue in conference and a full examination of the consequences of
passing this provision into law."
With her statement, Rep. Emerson, a long-time supporter of personal importation and the co-founder of the Affordable Medicine Caucus with Rep. Peter Welch (D-VT-At Large) has put Pharma on notice to not attempt to misinterpret the 'intent' of Section 805, and she has made the record on behalf of and support for personal importation.
Rep. Emerson's example should be an example for other legislators.
Attempts by PhRMA to co-opt legislation in the same manner that it dealt with a White House so desperate to enact a legacy bill that it violated the positions and principles that the American public embraced in Candidate Obama in 2008, must be opposed by the American public, who hopefully will rally in opposition to continued efforts at power grabs by unelected bureaucrats claiming the right to interpret implementation of legislation that could drastically affect the personal health and well-being of untold numbers of Americans.
Let's hope their legislators heed the sentiments of American citizens and not those of PhRMA.
Attempts by PhRMA to co-opt legislation in the same manner that it dealt with a White House so desperate to enact a legacy bill that it violated the positions and principles that the American public embraced in Candidate Obama in 2008, must be opposed by the American public, who hopefully will rally in opposition to continued efforts at power grabs by unelected bureaucrats claiming the right to interpret implementation of legislation that could drastically affect the personal health and well-being of untold numbers of Americans.
Let's hope their legislators heed the sentiments of American citizens and not those of PhRMA.
.